Acoustic Innovations

HistoSonics is a medical technology company pioneering the use of histotripsy, a non-invasive sonic beam therapy. Originally founded as Acoustic Innovations, the company developed the Edison System, which utilizes high-pressure ultrasound pulses to mechanically destroy targeted tissue at the sub-cellular level without the use of heat or ionizing radiation. This non-thermal approach allows for the precise destruction of tumors while sparing surrounding critical structures like blood vessels and bile ducts. The Edison System received FDA De Novo clearance in 2023 for the non-invasive destruction of liver tumors and is currently being evaluated for applications in kidney and pancreatic tissues. By providing a non-invasive alternative to surgery and ablation, HistoSonics aims to improve patient outcomes and reduce recovery times in oncology and other therapeutic areas.